Brief: Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update

Revance Therapeutics

09/05/2023 22:17

May 9 (Reuters) - Revance Therapeutics Inc  RVNC.O :
    * REVANCE REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS,
PROVIDES
CORPORATE UPDATE
    * TOTAL REVENUE FOR Q1 ENDED MARCH 31, 2023 WAS $49.3
MILLION
COMPARED TO $25.3 MILLION FOR SAME PERIOD LAST YEAR
    * EXPECTS 2023 GAAP OPERATING EXPENSES TO BE $460 MILLION TO
$480
MILLION
    * Q1 EARNINGS PER SHARE VIEW $-0.70, REVENUE VIEW $46.1
MILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID:nBw7zKlsca 
Further company coverage:  RVNC.O 

 ((Reutersbriefs@thomsonreuters.com;))